Spironolactone in Post-Transplant Proteinuria: A Safe Alternative Therapy

Transplantation Proceedings

Volumn 49, Issue 4, 2017, Pages 813-816

  de Sousa, M V ^a   Guida, J P ^a   do Valle, C F ^a   Camargo, L F ^a   Rivelli, G G ^a   Mazzali, M ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

SPIRONOLACTONE; DIURETIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DONOR; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEPHROSIS; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY;

ADULT; DIURETICS; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; RETROSPECTIVE STUDIES; SPIRONOLACTONE;

EID: 85018271857     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2017.01.075     Document Type: Article

References (10)

1. [1] Remuzzi, G., Cattaneo, D., Perico, N., The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 19 (2008), 1459–1462.
2. [2] Brown, N.J., Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 9 (2013), 459–469.
3. [3] Brem, A.S., Morris, D.J., Gong, R., Aldosterone-induced fibrosis in the kidney: questions and controversies. Am J Kidney Dis 58 (2011), 471–479.
4. [4] Lahmer, T., Hermans, R., Schmaderer, C., et al. Mineralocorticoid receptor antagonism and aldosterone synthesis inhibition do not improve glomerulosclerosis and renal interstitial fibrosis in a model of chronic kidney allograft injury. Kidney Blood Press Res 35 (2011), 561–567.
5. [5] Jenni, F., Riethmüller, S., Wüthrich, R.P., Significance of urine diagnostic tests after renal transplantation. Transplantation 37 (2013), 116–123.
6. [6] Shamseddin, M.K., Knoll, G.A., Posttransplantation proteinuria: an approach to diagnosis and management. Clin J Am Soc Nephrol 6 (2011), 1786–1793.
7. [7] Waanders, F., Rienstra, H., Boer, M.W., et al. Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats. Am J Physiol Renal Physiol 296 (2009), F1072–F1079.
8. [8] González Monte, E., Andrés, A., Polanco, N., et al. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months. Transplant Proc 42 (2010), 2899–2901.
9. [9] Bolignano, D., Palmer, S.C., Navaneethan, S.D., Strippoli, G.F.M., Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 29 (2014), 1–93.
10. [10] Chen, H., Sun, F., Zhong, X., et al. Esplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. Kidney Blood Press Res 37 (2013), 557–566.